votrient
novartis new zealand ltd - pazopanib hydrochloride 433.4mg equivalent to 400 mg pazopanib base; ; - film coated tablet - 400 mg - active: pazopanib hydrochloride 433.4mg equivalent to 400 mg pazopanib base excipient: magnesium stearate microcrystalline cellulose opadry white ys-1-7706-g povidone sodium starch glycolate - votrient is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (rcc).
votrient 400mg tablets
novartis pharmaceuticals uk ltd - pazopanib hydrochloride - tablet - 400mg
votrient 200mg tablets
novartis pharmaceuticals uk ltd - pazopanib hydrochloride - tablet - 200mg
votrient 400mg tablets film-coated
glaxo wellcome s.a. - pazopanib - tablets film-coated - 400mg
votrient 200mg tablets film-coated
glaxo wellcome s.a. - pazopanib - tablets film-coated - 200mg
votrient film-coated tablet 200mg
novartis corporation (malaysia) sdn. bhd. - pazopanib hydrochloride -
votrient film-coated tablet 400mg
novartis corporation (malaysia) sdn. bhd. - pazopanib hydrochloride -
votrient 200mg film-coated tablet
nvs kenya limited p.o box 46057-00100 gpo nairobi - pazopanib - film-coated tablet - 200mg - pazopanib
pazopanib stada 200 mg filmtabletten
pazopanib stada 400 mg filmtabletten